Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Memphasys Secures Exclusive Distribution Agreement with INVIDO LAB for Felix System
Memphasys nets exclusive Felix System deal with INVIDO LAB in Czech Republic, Slovakia, Kazakhstan; €416k min purchases, unlocking recurring cartridge revenue.
Latest Stories — SECTOR DESK
AdAlta Validates Commercial Viability of IRO Manufacturing Strategy with Oribiotech Deal
AdAlta's IRO platform earns commercial validation as Oribiotech inks a 10-year, up to US$120m deal to manufacture a marketed cell therapy in APAC.
Prescient Therapeutics Hits Enrolment Threshold for PTX-100 Phase 2a Trial Review
Prescient Therapeutics hits enrolment milestone: PTX-100 Phase 2a reaches 20 evaluable patients; first Dose Optimisation Committee review in December 2026.
Resonance Health Partners with UK CRO to Include SaMD Services in Global Clinical Trials
Resonance Health signs 24-month deal with UK CRO Image Analysis to add SaMD MRI endpoints to global trials, targeting obesity and metabolic disease.
Patrys Forms Advisory Committee to Guide Development of RLS-2202 Acute Delirium Injectable
Patrys forms international Clinical Advisory Committee to guide RLS-2202 delirium injectable, chaired by Dr Johnny Iliff, ahead of pivotal trials.
Ceretas Completes Key Ultrasound Development Milestone in CUREator+ Cognitive Decline Program
Ceratas completes CUREator+ milestone, unlocking $692k non-dilutive funding; IGN and lift-assist prototypes to cut costs and boost usability.
HeraMED to Deliver HeraCARE Hybrid Maternity Care Solution for Major US Health Network
HeraMED secures US$317k first-phase HeraCARE rollout with Lee Health System, kicking off commercial US expansion via SaaS, Epic EMR integration, 200 patients.
Prescient Therapeutics Advances Lead Asset PTX-100 through Phase 2a Trials as Pharmaceutical Dealmaking Accelerates
Prescient advances PTX-100 in Phase 2a for CTCL; DOC review set for Dec 2026 as Prescient accelerates toward registration data amid booming pharma dealmaking.
Lumos Diagnostics Adds Four US Urgent Care Groups to FebriDx Blood Test Rollout
Lumos Diagnostics expands FebriDx rollout to 215 US sites; two major health-system groups move to deployment across 40+ sites as validation widens to 45 sites.
Entropy Neurodynamics Confirms Durable Clinical Response in TRP-8803 BED Trial
Entropy Neurodynamics reports durable 12-week BED response from TRP-8803, with 50% binge-free and 73% weekly episodes below baseline after two doses.
Immutep Refocuses Efti Development Following TACTI-004 Study Review
Immutep refocuses eftilagimod alfa on HNSCC (CPS<1) and neoadjuvant STS after TACTI-004 review; new 200L manufacturing, target H2 2027 trial start.
Cleo Diagnostics Selects Bio-Techne’s US Laboratory for Pivotal Ovarian Cancer Test Validation
Cleo Diagnostics taps Bio-Techne's US lab for pivotal validation of its pre-surgical ovarian cancer test ahead of a 510(k) FDA filing in H1 2027.